stockrow
Friday 6 November 2026
Export PLUR’s income statement to Excel — free account
Pluri Inc.
PLUR Healthcare Biotechnology
Pluri Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.0 million, down 24.0% from fiscal 2025.
- Revenue
- −15.8%
- EPS
- +44.8%
- Free cash flow
- +25.0%
- Total debt
- +3.43%
Quarter to June 2026, against a year earlier
1.24
0.05
+4.20%
Follow PLUR
Alert me
Pluri Inc. (PLUR) P/E ratio
Pluri Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 23 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| NEUP Neuphoria Therapeutics Inc. compare | n/m |
| PLUR Pluri Inc. | n/m |
| MRKR MARKER THERAPEUTICS, INC. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | n/m |
| ATYR aTyr Pharma, Inc. compare | n/m |
| VAXX Vaxxinity, Inc. compare | n/m |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| ABOS Acumen Pharmaceuticals, Inc. compare | n/m |
| KYNB Kyntra Bio Inc compare | 0.1× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)